Tyra Biosciences (TYRA) Other Non-Current Liabilities (2020 - 2024)
Tyra Biosciences (TYRA) posted Other Non-Current Liabilities of $3000.0 for Q4 2024, down 72.73% on a QoQ basis from $11000.0 in Q3 2024, and down 93.48% year-over-year from $46000.0 in Q1 2024.
Tyra Biosciences (TYRA) Other Non-Current Liabilities (2020 - 2024) Analysis & Trends
Tyra Biosciences' Other Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $3000.0 for Q4 2024.
- Quarterly Other Non-Current Liabilities fell 93.48% year-over-year to $3000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $3000.0 (down 93.48% YoY) and the FY2024 annual result came in at $3000.0, down 93.48% from the prior year.
- Other Non-Current Liabilities was $3000.0 for Q4 2024 at Tyra Biosciences, down from $11000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $434000.0 in Q3 2021 and bottomed at $3000.0 in Q4 2024.
- A 5-year average of $155533.3 and a median of $139000.0 in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Other Non-Current Liabilities jumped 162.14% — and 2024, when it slumped 93.48%.
- Tyra Biosciences' Other Non-Current Liabilities stood at $140000.0 in 2020, then soared by 162.14% to $367000.0 in 2021, then plunged by 53.95% to $169000.0 in 2022, then slumped by 72.78% to $46000.0 in 2023, then slumped by 93.48% to $3000.0 in 2024.
- Business Quant data shows TYRA's Other Non-Current Liabilities at $3000.0 in Q4 2024, $11000.0 in Q3 2024, and $20000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Tyra Biosciences | 1.90 Bn | 1.90 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | 11,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 29,000.00 |
| Dec 31, 2023 | 46,000.00 |
| Sep 30, 2023 | 77,000.00 |
| Jun 30, 2023 | 108,000.00 |
| Mar 31, 2023 | 139,000.00 |
| Dec 31, 2022 | 169,000.00 |
| Sep 30, 2022 | 226,000.00 |
| Jun 30, 2022 | 261,000.00 |
| Mar 31, 2022 | 303,000.00 |
| Dec 31, 2021 | 367,000.00 |
| Sep 30, 2021 | 434,000.00 |
| Dec 31, 2020 | 140,000.00 |